305,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Vestal Point Capital LP

Vestal Point Capital LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 305,000 shares of the biopharmaceutical company's stock, valued at approximately $7,707,000. Vestal Point Capital LP owned approximately 0.46% of Celldex Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its stake in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV boosted its stake in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC boosted its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Celldex Therapeutics during the 4th quarter worth approximately $121,000.

Analysts Set New Price Targets

CLDX has been the subject of several research reports. UBS Group cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group cut their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Morgan Stanley cut their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group started coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Price Performance

CLDX traded down $0.02 during trading on Friday, hitting $20.35. The company's stock had a trading volume of 477,438 shares, compared to its average volume of 895,300. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The firm's 50 day moving average price is $18.91 and its 200-day moving average price is $22.42. The stock has a market cap of $1.35 billion, a PE ratio of -7.92 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.